Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa[1]. This low molecular weight allows it to cross the blood–brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain‑derived neurotrophic factor (BDNF)[1][2]. Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models[4][5]. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles[2][3].
